- Home
- PAM vs LSBPW Comparison
PAM vs LSBPW Comparison
Compare PAM & LSBPW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAM
- LSBPW
- Stock Information
- Founded
- PAM 1945
- LSBPW N/A
- Country
- PAM Argentina
- LSBPW China
- Employees
- PAM N/A
- LSBPW 758
- Industry
- PAM Electric Utilities: Central
- LSBPW Biotechnology: Pharmaceutical Preparations
- Sector
- PAM Utilities
- LSBPW Health Care
- Exchange
- PAM Nasdaq
- LSBPW Nasdaq
- Market Cap
- PAM 4.8B
- LSBPW N/A
- IPO Year
- PAM N/A
- LSBPW N/A
- Fundamental
- Price
- PAM $93.17
- LSBPW $0.08
- Analyst Decision
- PAM Buy
- LSBPW
- Analyst Count
- PAM 4
- LSBPW 0
- Target Price
- PAM $67.38
- LSBPW N/A
- AVG Volume (30 Days)
- PAM 241.2K
- LSBPW N/A
- Earning Date
- PAM 03-05-2025
- LSBPW N/A
- Dividend Yield
- PAM N/A
- LSBPW N/A
- EPS Growth
- PAM 166.38
- LSBPW N/A
- EPS
- PAM 0.47
- LSBPW N/A
- Revenue
- PAM $2,709,042,561.00
- LSBPW N/A
- Revenue This Year
- PAM N/A
- LSBPW N/A
- Revenue Next Year
- PAM N/A
- LSBPW N/A
- P/E Ratio
- PAM $9.05
- LSBPW N/A
- Revenue Growth
- PAM 221.02
- LSBPW N/A
- 52 Week Low
- PAM $38.15
- LSBPW N/A
- 52 Week High
- PAM $97.55
- LSBPW N/A
- Technical
- Relative Strength Index (RSI)
- PAM 59.47
- LSBPW N/A
- Support Level
- PAM $88.96
- LSBPW N/A
- Resistance Level
- PAM $96.90
- LSBPW N/A
- Average True Range (ATR)
- PAM 3.71
- LSBPW 0.00
- MACD
- PAM -0.18
- LSBPW 0.00
- Stochastic Oscillator
- PAM 66.40
- LSBPW 0.00
About PAM Pampa Energia S.A.
Pampa Energia SA and its subsidiaries are engaged in the Energy business. The operating business segments of the firm are Electricity generation, Electricity distribution, Oil and Gas, Petrochemicals, and Holding and other business. The company derives the maximum revenue from the Distribution of energy.
About LSBPW LakeShore Biopharma Co. Ltd
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.